This is a 1-day meeting and will provide 6 CE/CME credits.

Conference Registration Fee

Practicing Healthcare Professionals: $129

Register now >>

Non-Clinicians / Medical Office Support Staff / Industry Participants

In order to maintain the clinical nature of the conference, nonclinicians—including, but not limited to, office managers, billing specialists, receptionists, and administrative staff; guests, spouses, friends, and/or family members—may not attend PAINWeekEnd.

Please note: Discount room blocks are not available at this hotel. Please contact the hotel directly should you require accommodations.

San Diego Marriott Mission Valley
8757 Rio San Diego Dr.
San Diego, CA 92108

View hotel website >>

Get Directions using Google Maps

Faculty and courses are subject to change. Please refer to the online agenda below for the most recent course descriptions.

To view the agenda below, click on the + sign next to the day of the conference to expand the conference agenda. Click on the + signs within the agenda to view the course description, UAN number, and AANP pharmacology credits.

Schedule subject to change.

Saturday, June 13, 2020


    Coffee will be served.

  • Episodic Versus Chronic Migraine: An Update on Novel and Emerging Therapeutic Options

    Why yet another lecture on migraine headaches, you ask? Migraine is the third most common disease in the world (behind dental caries and tension-type headache) with an estimated global prevalence of approximately 15% (that's around 1 in 7 people). Migraine is more prevalent than diabetes, epilepsy, and asthma combined. There continues to be a lack of education on primary headache disorders in clinical training and an underappreciation for the importance of aggressive treatment. This lecture will focus on distinguishing between episodic and chronic migraine, providing the audience with updates on diagnostic guidelines and the latest in current and emerging therapies.

    • UAN: 0530-0000-20-037-L01-P
    • AANP Rx Hours: 0.10

    Breakfast will be served.

    *This session is not certified for credit.


  • He SAID, She SAID. What's the Deal with NSAIDs?

    Safety concerns, new warnings, and new formulations focused on harm reduction have led many providers to question NSAIDs place in therapy. NSAIDs have been a cornerstone of pain management of inflammatory, connective tissue, and autoimmune disorders for over a hundred years. A historical perspective is key to understanding the role of NSAIDs in pain management, and a therapeutic update on current evidence will aid providers in practical utilization. The safety of NSAIDs will be reviewed and compared to risks of other medications including opioids. New FDA warnings on cardiovascular risk of NSAIDs will be placed into context and examples of clinical decision-making provided. In addition, new formulations of NSAIDs will be discussed including IV NSAIDs, topical NSAIDs, and new micronized NSAIDs.

    • UAN: Coming soon.
    • AANP Rx Hours: Coming soon.
  • Interventional Pain Management: Opioid-Sparing Technologies

    The ancient Sumerians first cultivated the poppy plant for its opium in 3000 BC. The analgesic properties of opium were formalized into morphine and later commercialized by Merck Pharmaceuticals in 1827. To this date, morphine and its derivatives are effectively used for treating acute pain. In recent years, however, the overuse of opioids to treat chronic nonmalignant pain has contributed to the prescription opioid epidemic. As society has recognized this problem and our government has stepped into opioid crisis efforts, we turn to technology in treating chronic pain as an alternative to opioid medications. This presentation is targeted for general practitioners and current pain management physicians. We will explore the evolution of pain medicine leading up to the current and future opioid-sparing interventional pain treatment options. Specifically, we will focus on electroceuticals (spinal cord stimulation, peripheral nerve stimulation, vagus nerve stimulation), minimally invasive spinal decompression spacers, and percutaneous sacroiliac joint fusion.

    • UAN: 0530-0000-20-029-L01-P
    • AANP Rx Hours: Coming soon.



    Lunch will be served.

    Sponsored by AstraZeneca-Daiichi Sankyo, Inc.

    *This session is not certified for credit.

  • Spinal Stenosis: Epidemiology, Pathophysiology, and Treatment

    Degenerative lumbar spinal stenosis (LSS) is the most common form of acquired spinal stenosis caused by biomechanical narrowing of the spinal canal and the associated neuroforamen that eventually lead to compression of neural fibers resulting in pain and disability. Neurogenic claudication as a result of lumbar spinal stenosis is a common chronic pain condition that is often difficult to treat due to paucity of effective minimally invasive options. Patients who exhaust conservative means usually have short term pain relief with epidural steroid injections prior to being offered open lumbar decompression surgery. LSS is a progressive, age related degenerative process that causes narrowing of the lumbar spinal canal. More than 1.2 million patients in the US are diagnosed with spinal stenosis each year, and the number is expected to rise as our population matures. This presentation will focus on the epidemiology, pathophysiology, and treatment options available for spinal stenosis. There will be discussions relating to the health economics of spinal stenosis as it pertains to disability and cost of treatment. We will specifically focus on some of the recently available minimally invasive options such as indirect interspinous decompression and minimally invasive lumbar decompression.

    • UAN: 0530-0000-20-034-L01-P
    • AANP Rx Hours: Coming soon.


    Refreshments will be served.

    *This session is not certified for credit.

  • Everybody’s Greasing Up, But Should You Rub It In? A Review of Topical Analgesics and Available Evidence in Clinical Trials

    Topical analgesics are often recommended in clinical practice, but differences between formulations and routes of administration lead to confusion. In addition to commercially prepared topical analgesics, compounded topical analgesics are highly promoted and widely utilized from compounding pharmacies with individualized recipes of multiple combined medications, at substantial cost. To assist providers with tough decisions in this area, the available clinical trials supporting use will be reviewed along with formulations, locations, and doses where their use have been shown to the be most effective. This session will review the role of various topical analgesics as well as explore the rationale for “topical polypharmacy” with compounded drugs.

    • UAN: 0530-0000-20-028-L01-P
    • AANP Rx Hours: Coming soon.
  • Medicinal Cannabis: What You & Your Patients Need to Know

    With 47 states having passed legislation for the use of medicinal cannabis in some form or another, and the growing number of states passing legislation allowing for the use of recreational cannabis by their residents, the country is awash with green. Does cannabis have true utility as a medicine? What about addiction, psychosis, drug interactions, and driving under the influence? These and many other questions will be answered and discussed in this updated lecture.

    • UAN: 0530-0000-20-038-L01-P
    • AANP Rx Hours: Coming soon.


To accompany and enrich your experience at the PAINWeekEnd conference, be sure to attend one or more of the sponsored programs, which are scheduled during breakfast, lunch, and afternoon "Brain Food" time slots in the schedule. There is NO ADDITIONAL CHARGE to attend these program sessions!